378 related articles for article (PubMed ID: 12812266)
1. Hyperhomocysteinemia and end-stage renal disease: determinants and association with cardiovascular disease in Tunisian patients.
Fellah H; Feki M; Hsairi M; Sanhaji H; Kaabachi N; Ben Abdallah T; Massy ZA; Ben Maiz H; Lacour B; Mebazaa A
Clin Chem Lab Med; 2003 May; 41(5):675-80. PubMed ID: 12812266
[TBL] [Abstract][Full Text] [Related]
2. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
Lovcić V; Kes P; Zeljko R; Kusec V
Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients.
Bostom AG; Shemin D; Gohh RY; Beaulieu AJ; Bagley P; Massy ZA; Jacques PF; Dworkin L; Selhub J
Kidney Int Suppl; 2001 Feb; 78():S246-52. PubMed ID: 11169020
[TBL] [Abstract][Full Text] [Related]
4. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients.
Suliman ME; Qureshi AR; Bárány P; Stenvinkel P; Filho JC; Anderstam B; Heimbürger O; Lindholm B; Bergström J
Kidney Int; 2000 Apr; 57(4):1727-35. PubMed ID: 10760109
[TBL] [Abstract][Full Text] [Related]
5. [Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients].
Armada E; Pérez Melón C; Otero A; Gayoso P; Rodríguez M; Esteban Morcillo J
Nefrologia; 2001; 21(2):167-73. PubMed ID: 11464650
[TBL] [Abstract][Full Text] [Related]
6. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS
J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754
[TBL] [Abstract][Full Text] [Related]
7. Hyperhomocysteinemia is related to residual glomerular filtration and folate, but not to methylenetetrahydrofolate-reductase and methionine synthase polymorphisms, in supplemented end-stage renal disease patients undergoing hemodialysis.
Anwar W; Guéant JL; Abdelmouttaleb I; Adjalla C; Gérard P; Lemoel G; Erraess N; Moutabarrek A; Namour F
Clin Chem Lab Med; 2001 Aug; 39(8):747-52. PubMed ID: 11592445
[TBL] [Abstract][Full Text] [Related]
8. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease.
Wrone EM; Zehnder JL; Hornberger JM; McCann LM; Coplon NS; Fortmann SP
Kidney Int; 2001 Sep; 60(3):1106-13. PubMed ID: 11532106
[TBL] [Abstract][Full Text] [Related]
9. [Hyperhomocysteinemia, oxidative stress and microinflammation in chronic renal failure: their roles in atherogene].
Yu YM; Hou FF; Zhang X; Zhou H; Liu ZQ
Zhonghua Nei Ke Za Zhi; 2004 Apr; 43(4):292-5. PubMed ID: 15130417
[TBL] [Abstract][Full Text] [Related]
10. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
Sjöberg B; Anderstam B; Suliman M; Alvestrand A
Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
[TBL] [Abstract][Full Text] [Related]
11. Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins.
Tremblay R; Bonnardeaux A; Geadah D; Busque L; Lebrun M; Ouimet D; Leblanc M
Kidney Int; 2000 Aug; 58(2):851-8. PubMed ID: 10916110
[TBL] [Abstract][Full Text] [Related]
12. Homocysteine and risk of cardiovascular disease.
Andreotti F; Burzotta F; Manzoli A; Robinson K
J Thromb Thrombolysis; 2000 Jan; 9(1):13-21. PubMed ID: 10590184
[TBL] [Abstract][Full Text] [Related]
13. The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels.
Galli F; Benedetti S; Buoncristiani U; Piroddi M; Conte C; Canestrari F; Buoncristiani E; Floridi A
Kidney Int; 2003 Aug; 64(2):748-55. PubMed ID: 12846775
[TBL] [Abstract][Full Text] [Related]
14. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein.
Busch M; Franke S; Müller A; Wolf M; Gerth J; Ott U; Niwa T; Stein G
Kidney Int; 2004 Jul; 66(1):338-47. PubMed ID: 15200442
[TBL] [Abstract][Full Text] [Related]
15. Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy.
Suliman ME; Stenvinkel P; Heimbürger O; Bàràny P; Lindholm B; Bergström J
Am J Kidney Dis; 2002 Sep; 40(3):480-8. PubMed ID: 12200798
[TBL] [Abstract][Full Text] [Related]
16. [Characteristics of hyperhomocysteinemia in dialysis patients].
Lovcić V; Kes P; Reiner Z
Acta Med Croatica; 2006; 60(1):21-6. PubMed ID: 16802568
[TBL] [Abstract][Full Text] [Related]
17. Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations.
McGregor DO; Dellow WJ; Lever M; George PM; Robson RA; Chambers ST
Kidney Int; 2001 Jun; 59(6):2267-72. PubMed ID: 11380830
[TBL] [Abstract][Full Text] [Related]
18. Serum total homocysteine concentration before and after renal transplantation.
Arnadottir M; Hultberg B; Wahlberg J; Fellström B; Dimény E
Kidney Int; 1998 Oct; 54(4):1380-4. PubMed ID: 9767559
[TBL] [Abstract][Full Text] [Related]
19. Total serum homocysteine, folate and vitamin B12 in a Greek school age population.
Papandreou D; Mavromichalis I; Makedou A; Rousso I; Arvanitidou M
Clin Nutr; 2006 Oct; 25(5):797-802. PubMed ID: 16690175
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis.
Moustapha A; Gupta A; Robinson K; Arheart K; Jacobsen DW; Schreiber MJ; Dennis VW
Kidney Int; 1999 Apr; 55(4):1470-5. PubMed ID: 10201012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
